MELBOURNE, Australia, June 27, 2022 /PRNewswire/ — Incannex Healthcare Limited (NASDAQ: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) a clinical-stage pharmaceutical company developing unique medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for unmet medical needs, today announced that Dr. Paul Liknaitzky, Head of Clinical Psychedelic Research at Monash University…


Previous articlePsychedelic Bulletin #108 – COMPASS Survives Patent Challenges; MindMed Secures Candyflipping IP; Will Psychedelics Companies Protect Access to Abortion for Employees?
Next articlePT332 – James Lanthier – Patentability, Capitalism, and The Next Generation of Psychedelics